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Cost-Effectiveness of Intracoronary Stents 
Sunday, March 29, 1998, 5:00 p.m.-7:00 p,m. 
Georgia World Congress Center, West Exhibit Hall Level 
Presentation Hour: 5:00 p.m,-7:00 p.m, 
~ Cardiac Interventlonel Procedurea Performed In 
Europe Ourlng e Four Year Observation Period 
From 1992 to 1995 
S, Wlndo~ksr, B,J, Meyer, B, Molar, On betflllf of the working gmt~p: 
Coronary CIK:ldatton of the European Society of C(Irdlolegy, University 
Hospital f~em, Swttt.erl~nd 
gackgm¢lnd: An annual survey on pomutanoous cardiac interventions I~n8 
boon conducted by tho European Society of Cardiology 81nee 1992, The 
p~.~rposa of this study was to analy~o the trends in cardiac intervention8 
during this observation period, 
Method~/Res)df~: A quoMton~iro wo~l distributed through the nattonnl 
societies ol c~rdlology to 35 m~mbor ~t~tes el the European Society el 
Cerdlology, The questionnaire conlains a detailed II~lieg el all porcl.d~ncous 
e~rdlac Interventions, The results ol thI~ survey sm summarized in t11o table 
below: 
191}2 10~3 1004 191"15 
C~lh'~ (103 Illl~ 7f~11 8,~2 fl~ )'iS? l O~2 tfl~ 
P]'CA't,, 147' T;,~O Ifi3 t;~9 ~,t 7~ 27~ )0S 
~lanls 3 ~11 o 444 21 509 7,6 056 
PTO,'VCABCt t i 1 ~ 1 3 t s 
Conchl,~tons: t, The number o! eoronnn/ anglogrnms increases at an 
~nnusl rat(} of 15%. 2. The number ot PTCA's Increases at an annual rate 
o! 20% 3, Coronas/stontlng Is the fastest growing procedure in intorven. 
ttonal cardiology. 4. PTCA eontlnuo.~ to stffpnss CABG as mvnsculartzation 
p~codure, 
I~1~ Appll©atlon of Critical Pathways In the 
........ Introduction of New Medical Technology: The 
Intra©oronary Stent as a Model 
H.D, Aronow, K,A, Eagle, E,R, Bates, S,W, Woms, D,W,M, Muller, 
E, Kilns-Rogers, D,J, Knr~vite, P,L Russmnn, M Moscucci, The Univer~fty 
of Michtg,qn, Ann Arbor, MI, US4 
After the initial research breakthrough, new medical technology can be further 
developed, improved, and adapted to now indications. By standardizing and 
optimizing the cam process, critical pathways (CP) may facilitate the introduc- 
tion of now medical technology and the rapid implementation el changes in 
ancdlary care. The development el intracoronan/stenting, with the evolution 
in pen-procedural care and antico0Lgulation regimen, is a useful paradigm. 
We report our oxpenonco with intracorenan/steeling as a model for CP ap- 
plication. Between 8/10~3 and 3/31/97, 494 consecutive patients unden~ent 
intracoronary slanting for stable or unstable coronary syndromes during 4 
phases el CP evolution (Periods A through D). During that time, tighter blood 
pressure control was implemented, sheath removal practices were revised 
and the pori-procedural antlcoagulation regimen was progressively liberal- 
ized from one that included dextren. IV hoparin, warfarin at a target INR of 
3-4, dipyndamole end ASA (A), to a final regimen that contained neither 
post-procedure heparin nor wartann ([32). As treatment algorithms evolved, 
vascular complication rate (VC), blood transfusion rate (Txt) end post-pro- 
cedure length.of-stay (LOS) decreased signilicantly without a consequent 
increase in the rate of subacute stent thrombosis (SST). 
Period In) A (30) B (91 C 118) D1 (146) 92 1291) p 
Txl (%) 400 22 2 16.7 15 '; 4,1 0,001 
VC (%) 16 7 0 50  5.5 2 7 0008 
LOSd~ys) 98  t 77 58  ~ 08  46  ~ 15 55  ~ 5,3 22 ~ 39 , 0001 
SST (%) O 0 0 1 4 07  0.869 
The observed reduction in complication rates and LOS was tikeIy the 
result of changes in anticoaguiatmn regimen. The CP proved instrumental 
in facilitating the rapid and controlled introduction of changes in the care 
process and in tracking the effects of ,hose changes on clinical outcomes. 
~ C o s t  of  Cl in ical  Restenosis and 
Cost-effectiveness of Therapy to  P revent  it 
W.S. Weintraub. Emery University. Atlanta, GA. USA 
Restenosis, a major limitation of PTCA, increases cost by adding resource 
use, especially repeat procedures. Recently rostonosls has boon defined 
clinically. And for this study was defined as death, myocardial infarction. 
additional PTCA or CABG offer suecosslul, u~¢ump.cated therapy, Charges 
for additional hospitalizations worn determined from the UB92 forms, and 
reduced to cost by doparlmeet81 cost to charge ratio, cost are expressed 
1996 dollem. Between 1988 and 1995 them were 5,799 patients suitable 
for study with cost date available, The cost o1 cllnlcsl melanesia (n ,~ 1,131 
or 19,5%) was $9,633 (25% to 75% range $7,453 to $11,813), Them woe 
limited ability to predict clinical m,'~tenosls (area und0r ROC curve 0,60) and 
even loss to predict th~ cost (r'~ ~. 3,05), Thus n ault0ble preventive therapy 
will pmbsbly be used in all possible patients, It the effectiveness of preventive 
therapy Is 80% ~nd the cost el therapy $2,500, it will cost $16,000 P0r event 
prevented', I1 oo~t 01 therapy ie $1,000, cost p~r event prevented falls to 
$633, 
i 
Effectiveness 
Tl~o figure is a two way sensitivity analyms o1 effectiveness el preventive 
therapy from 10% to 1C0% and each line Irom bottom to top, is an isobar el 
Cost from $500 to $5000 in $500 steps. Cost effectiveness (C-E) ~mproves 
with lower cost of therapy and improved effectiveness Rostonosts is likely to 
remain a problem ~lter PTCA until inexpensive, highly effective prevenhve 
therapy ts evadable. 
Cost effectiveness analysis may help gu~do the choice of therapy :3rid m 
~etting policy over use of ~careo resources. 
~ Costs and Effects of Stent Implantation Versus 
Ba l loon  Angloplasty 
BA. van Hour I , O.J. Cohen "~, BAH Keens ~, PW. Sorruys ~ . 'lastltute for 
Medical Technology Assessment, Erasmus University Rotterdam. 
Netherlands: ~Outch Centre for Health Economics and System Science. 
Rotterdam. Netherlands: "~ Thoraxcentre Academic Hospital. Rotterdam. 
Netherlands: CBeth Israel Hospital. Boston MA. USA 
Background. The Benestent II study is designed not only to assess salary and 
efficacy el the hepann coated Palmaz-Schatz stent but also to investigate 
the balance between the costs and effects. 
Methods: Cost effectiveness is estimated at one year alter randomization 
D~rect medical costs am calculated by multiplying detailed resource utilization 
data with US, cost estimates. Effects are expressed in terms el event tree 
survival including death, MI, stroke and all re-interventions as events. Cost 
effectiveness is expressed in terms el incremental cost effectiveness ratio's. 
Subgroup analyses concern LAD. vessel size :.3 mm and stablo/unstable 
angina 
Results: Event tree survival is estimated at 88.8% alter stont implantation 
and at 790% after PTCA. The additional costs per additional event free 
survivor am estimated at $14,473 (95% CI: $ .  1,523-894,073). Subgroup 
analysis shows more favorable results for slant implantation in LAD lesions. 
in lesions with vessel size -3 mm. and in patients with unstable angina. Cost 
savings are expected for patients with a lesion in the LAD and a vessel size 
.3 mm ($11,481 for slant implantation versus $14.558 for PTCA). Here. the 
upper 95% limit of the incremental cost effectiveness ratio is estimated at 
$3,119. 
Conclusion: A strategy of stent implantation in all patients is more effective 
but also more costly than a strategy starting with PTCA (and a stnct definition 
of bail out steeling). Appropriate patient selection (LAD. vessel size :. 3 mm) 
however, may lead to cost savings. 
1 • - 2 7 - 5 1  I Clinical, Resource and Cost Benefits of the 
RESTORE Study  App l ied  to  US Populat ion 
S,J. Boccuzzi, J.B. Roehm, J,R. Cook, J,C. Burnette, S. Culler, 
W.S. Weintraub. Merck and Co. Inc., West Point PA: Emery Universi~ 
Atlanta, GA, USA 
RESTORE, a randomized efficacy study of tirofiban for outcomes and r-- 
stenosis, evaluated the effectiveness, resource utilization and cost of lib/Ilia 
JA(XI~' Fchmar~ lqqX .~II~'IRA(~I~ I',,~I¢= fil?t 
platolot inhibition m patients with acuto coronary ischomtc .~yn~romos un- 
dergoing angioplO.~ty RESTORE demonstrated a 30% .sk ,,e.Juu,on in the 
composite ondpoint el dosth, MI and repeat procedures (p = 0016) at 7 days 
and at 30 days (p = 0052) To proioct the chnicaL resource and cost linitml 
and 30 day) b~nohts ot~.~orved *n RESTORE to the eat!to US population 
(USP), the N~tmnal Hospital Discharge Sun/cry (NHDS) was utilized to i~m 
tifi~l a coheff of patients m~tm9 RESTORE eligibility cntetia NHDS PTCA 
o~timato5 for the US population for 1994 were approximately 404,000 Mor* 
bidity arxt rosou~e utilization rato~ fron~ RESTORE were applied to t~, USP 
PTCA estimates ~0 determine the ipop~!~tmn incremental bene~ fits of tirotiban 
therapy compafl~l to placebo An estimated reductmn ot approximately 64fi4 
Ml's ~nd 7;~72 emo~loncy repeat a~ast ies  would at~o be avoided at Day 
7, A ¢ommensmat~ f~g,~ion of $17,5,7 Million in inqiat hospit~li~RtJen Costs 
and $787 I~ MIIIio~ in overall costs, excluding drug procurement co,st, wogt~ 
bo eq~'Cled wlth tirofiban therapy Tlmfib~n confem the afqrcmentio~ c!in. 
ieal ~dvanta~ ~llh substanba! CoSt offsets du.ng the initial ho~p~ta!ization 
and 30 d~ys POSt hospitaliz~tmn 
• COII~!fect!ven~Is Ab¢iximab Coronary Of After 
S! .efil!ng: A Oe¢ls!on-analYlt~ Model 
O, Rodnguez, DE Cutiip, RE  Kuntz, O J. Cohen Beth Israel Deacones~ 
&~]~cat Cent~, BosUn. MA. USA 
B~ckgrou~. Abclxim¢Ib (AB) h~,s been shown tO mlprove ~ar~omes aMer 
bottoon angtopias~/but a  an increased cost Whether ~ts bet~hls ~pply aflef 
corc ~an~ tentmg (CS) ana at what co~ ~s not known 
Mortals Wo Oovoloped a ~I  to predict 1he co~Peflect~vene~s (CEi ot 
A['t u~e tn planned CS Baseh~ assumpl=on~ were d~fw¢~ from pubii~heCl 
¢t~la, ana included the annual probab~hly ot cafdra¢ Oeath for pts ~ cor~ 
~/d~so~se (range 0.6%~'9% depending on anatomy, LV f~ncbo~a and 
d~abetes): the ml~tiv~ rlsk (RR) of c~diac motla!ify ~ to pen~proc~ral 
CK el~vation (6% incma~ per 14otd rico in the fat~o Of ~k  CKtnOn~l) 
anq the RR o! p~ri.pt~oceduml CK elevation with AB (0,48). Th@ ~! .  
ity Ot pee@ro~edurat CK elevation (PCK) in pts undergoing C$ (10%) was 
bas~i on d~la from the Steel AntHhmmbot~ R~n St~fy (STAR~), We 
~s~ an AB cost Ot $!,400 and tha; perPproc~raI CK elevation wos~d 
affect cart~zte mort~!lity for 5 years. 
Resut~: The bafseline anatysis for a 60 year ~ n~n six,wed a CE tat'to 
el $6~0,000 Ip~r Y~r O! life= saved (YOLS) for low Osk pts (1.vessel dif=ease. 
no diabeles, normal election fraction) and of $1 fiT,OOO/YOLS for h~gh risk pts 
(mqlt~vessel d~sease, diat)etes, and low election trac1~on)~ Sens~tivOy aealy~is 
showed that malqr determinants Of C[~ were the cost of AB and pCK At a 
~p~ndtng threshold of $50,OGO,~'OLS, AB would be preteffed =n hi(]h ask pts 
d pCK was 35% or ~f it Cost ::.~100 For low ask pts, a~chlevement of a 
tavoml3le CE raho required t?oth a pCK 35% and a net AB cost $400 
Conctu~n The use of AB adtun~'Irvo t CS does net appear COSt-effec. 
t=vO ~n rousne use. Achievement ot CE rat~os comps.able tO other medical 
prast~ces ~equ=res target:ng Of pts at h~gh ns~ tot i3;e cardiac events and 
pen-p~oce~tufal CK elevations 
